- Home
- IIM vs REPL Comparison
IIM vs REPL Comparison
Compare IIM & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIM
- REPL
- Stock Information
- Founded
- IIM 1993
- REPL 2015
- Country
- IIM United States
- REPL United States
- Employees
- IIM N/A
- REPL N/A
- Industry
- IIM Investment Managers
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- IIM Finance
- REPL Health Care
- Exchange
- IIM Nasdaq
- REPL Nasdaq
- Market Cap
- IIM 551.6M
- REPL 578.4M
- IPO Year
- IIM N/A
- REPL 2018
- Fundamental
- Price
- IIM $12.08
- REPL $7.71
- Analyst Decision
- IIM
- REPL Strong Buy
- Analyst Count
- IIM 0
- REPL 6
- Target Price
- IIM N/A
- REPL $20.00
- AVG Volume (30 Days)
- IIM 122.2K
- REPL 1.1M
- Earning Date
- IIM 01-01-0001
- REPL 05-19-2025
- Dividend Yield
- IIM 4.63%
- REPL N/A
- EPS Growth
- IIM N/A
- REPL N/A
- EPS
- IIM 0.02
- REPL N/A
- Revenue
- IIM N/A
- REPL N/A
- Revenue This Year
- IIM N/A
- REPL $31.16
- Revenue Next Year
- IIM N/A
- REPL N/A
- P/E Ratio
- IIM $591.50
- REPL N/A
- Revenue Growth
- IIM N/A
- REPL N/A
- 52 Week Low
- IIM $9.94
- REPL $4.92
- 52 Week High
- IIM $12.32
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- IIM 63.25
- REPL 39.21
- Support Level
- IIM $11.64
- REPL $6.93
- Resistance Level
- IIM $12.05
- REPL $10.30
- Average True Range (ATR)
- IIM 0.13
- REPL 0.73
- MACD
- IIM 0.06
- REPL -0.07
- Stochastic Oscillator
- IIM 98.48
- REPL 23.15
About IIM Invesco Value Municipal Income Trust
Invesco Value Municipal Income Trust is a diversified, closed-end management investment company. Its investment objective is to provide common shareholders with current income which is exempt from federal income tax.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.